Molecular basis and therapeutic targets in prostate cancer: A comprehensive review
Militaru, Florentina Claudia, Militaru, Valentin, Crisan, Nicolae, Bocsan, Ioana Corina, Udrea, Anghel Adrian, Catana, Andreea, Kutasi, Eniko, Militaru, Mariela Sanda
Published in Biomolecules & Biomedicine (01.10.2023)
Published in Biomolecules & Biomedicine (01.10.2023)
Get full text
Journal Article
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Shah, Manish A, Udrea, Anghel Adrian, Bondarenko, Igor, Mansoor, Was, Sánchez, Raquel Guardeño, Sarosiek, Tomasz, Bozzarelli, Silvia, Schenker, Michael, Gomez-Martin, Carlos, Morgan, Carys, Özgüroğlu, Mustafa, Pikiel, Joanna, Kalofonos, Haralabos P, Wojcik, Elzbieta, Buchler, Tomas, Swinson, Daniel, Cicin, Irfan, Joseph, Mano, Vynnychenko, Ihor, Luft, Alexander Valerievich, Enzinger, Peter C, Salek, Tomas, Papandreou, Christos, Tournigand, Christophe, Maiello, Evaristo, Wei, Ran, Ferry, David, Gao, Ling, Oliveira, Joana M, Ajani, Jaffer A
Published in Cancers (24.02.2022)
Published in Cancers (24.02.2022)
Get full text
Journal Article
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard
Published in British journal of cancer (13.10.2016)
Published in British journal of cancer (13.10.2016)
Get full text
Journal Article
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs, Charles S, Tabernero, Josep, Tomášek, Jiří, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha A, Filip, Dumitru, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A, Hozak, Rebecca R, Ferry, David, Caldwell, C William, Ajani, Jaffer A
Published in British journal of cancer (11.10.2016)
Published in British journal of cancer (11.10.2016)
Get full text
Journal Article
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard
Published in British journal of cancer (08.11.2016)
Published in British journal of cancer (08.11.2016)
Get full text
Journal Article
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC)
Catenacci, Daniel V.T., Kang, Yoon-Koo, Saeed, Anwaar, Yamaguchi, Kensei, Qin, Shukui, Lee, Keun-Wook, Kim, In-Ho, Oh, Sang Cheul, Li, Jin, Turk, Haci M., Teixeira, Alexandra Carolina, Borg, Christophe, Hitre, Erika, Udrea, Anghel Adrian, Cardellino, Giovanni Gerardo, Guardeno, Raquel, Mitra, Siddhartha, Yang, Yingsi, Enzinger, Peter C., Wainberg, Zev A.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A comprehensive review on the molecular basis and therapeutic targets in prostate cancer
Militaru, Florentina Claudia, Militaru, Valentin, Crisan, Nicolae, Bocsan, Ioana Corina, Udrea, Anghel Adrian, Catana, Andreea, Kutasi, Eniko, Militaru, Mariela Sanda
Published in Biomolecules & biomedicine (04.04.2023)
Published in Biomolecules & biomedicine (04.04.2023)
Get full text
Journal Article
Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC)
Kim, Tae Won, Elme, Anneli, Park, Joon Ho, Udrea, Anghel Adrian, Manojlovic, Nebojsa S., Guan, Xuesong, Jung, A. Scott, Vrdoljak, Eduard
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB
Ajani, Jaffer A., Udrea, Anghel Adrian, Sarosiek, Tomasz, Schenker, Michael, Morgan, Carys, Pikiel, Joanna, Joseph, Mano, Salek, Tomas, Tournigand, Christophe, Ferry, David Raymond, Zhang, Yawei, Long, Amanda, Kuo, Wen-Ling, Gao, Ling, Russo, Francesca, Mansoor, Wasat
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer
Kim, Tae Won, Elme, Anneli, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Manojlovic, Nebojsa, Guan, Xuesong, Lofton-Day, Catherine, Jung, A. Scott, Vrdoljak, Eduard
Published in Clinical colorectal cancer (01.09.2018)
Published in Clinical colorectal cancer (01.09.2018)
Get full text
Journal Article
Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer
Vrdoljak, Eduard, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Villalobos, Ricardo, Srinivasan, Krishnan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A. Scott, Kim, Tae Won
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC)
Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Villalobos Valencia, Ricardo, Srinivasan, Krishnan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A. Scott, Vrdoljak, Eduard
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC
Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Villalobos Valencia, Ricardo, Srinivasan, Krishnan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A. Scott, Vrdoljak, Eduard
Published in Journal of clinical oncology (01.02.2016)
Published in Journal of clinical oncology (01.02.2016)
Get full text
Journal Article
Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL)
Fuchs, Charles S., Tabernero, Josep, Tomasek, Jiri, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha Ali, Dumitru, Filip, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A., Hozak, Rebecca R., Ferry, David, Caldwell, William, Ajani, Jaffer A.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
Cunningham, David, Tebbutt, Niall C., Davidenko, Irina, Murad, André M., Al-Batran, Salah-Eddin, Ilson, David H., Tjulandin, Sergei, Gotovkin, Evgeny, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki Abdulaziz, Udrea, Anghel Adrian, Tehfe, Mustapha Ali, Baker, Nigel, Oliner, Kelly Smith, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Catenacci, Daniel Virgil Thomas
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article